Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):207-12. doi: 10.1007/s00259-012-2265-y. Epub 2012 Oct 11.

Dosimetry of 223Ra-chloride: dose to normal organs and tissues.

Author information

  • 1Department of Nuclear Medicine, University of Würzburg, 97080 Würzburg, Germany. lassmann@nuklearmedizin.uni-wuerzburg.de

Abstract

PURPOSE:

(223)Ra-Chloride (also called Alpharadin®) targets bone metastases with short range alpha particles. In recent years several clinical trials have been carried out showing, in particular, the safety and efficacy of palliation of painful bone metastases in patients with castration-resistant prostate cancer using (223)Ra-chloride. The purpose of this work was to provide a comprehensive dosimetric calculation of organ doses after intravenous administration of (223)Ra-chloride according to the present International Commission on Radiological Protection (ICRP) model for radium.

METHODS:

Absorbed doses were calculated for 25 organs or tissues.

RESULTS:

Bone endosteum and red bone marrow show the highest dose coefficients followed by liver, colon and intestines. After a treatment schedule of six intravenous injections with 0.05 MBq/kg of (223)Ra-chloride each, corresponding to 21 MBq for a 70 kg patient, the absorbed alpha dose to the bone endosteal cells is about 16 Gy and the corresponding absorbed dose to the red bone marrow is approximately 1.5 Gy.

CONCLUSION:

The comprehensive list of dose coefficients presented in this work will assist in comparing and evaluating organ doses from various therapy modalities used in nuclear medicine and will provide a base for further development of patient-specific dosimetry.

PMID:
23053328
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk